Granahan Investment Management LLC Purchases Shares of 122,767 ChemoCentryx, Inc. (NASDAQ:CCXI)
Granahan Investment Management LLC Purchases Shares of 122,767 ChemoCentryx, Inc. (NASDAQ:CCXI)
Granahan Investment Management LLC purchased a new stake in shares of ChemoCentryx, Inc. (NASDAQ:CCXI – Get Rating) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 122,767 shares of the biopharmaceutical company's stock, valued at approximately $3,078,000. Granahan Investment Management LLC owned 0.18% of ChemoCentryx at the end of the most recent reporting period.
根據Granahan Investment Management LLC提交給美國證券交易委員會(SEC)的最新13F文件,該公司在第一季度購買了ChemoCentryx,Inc.(納斯達克代碼:CCXI-GET Rating)的新股份。該機構投資者購買了這家生物製藥公司的122,767股股票,價值約3,078,000美元。在最近的報告期結束時,Granahan Investment Management LLC擁有ChemoCentryx 0.18%的股份。
A number of other hedge funds also recently bought and sold shares of CCXI. Pictet Asset Management SA acquired a new position in shares of ChemoCentryx during the fourth quarter valued at about $58,453,000. Millennium Management LLC raised its position in shares of ChemoCentryx by 1,663.6% during the fourth quarter. Millennium Management LLC now owns 1,228,224 shares of the biopharmaceutical company's stock valued at $44,720,000 after buying an additional 1,306,776 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of ChemoCentryx during the fourth quarter valued at about $30,184,000. Sofinnova Investments Inc. raised its position in ChemoCentryx by 6,040.6% in the fourth quarter. Sofinnova Investments Inc. now owns 731,222 shares of the biopharmaceutical company's stock worth $26,624,000 after purchasing an additional 719,314 shares in the last quarter. Finally, GW&K Investment Management LLC acquired a new position in ChemoCentryx in the fourth quarter worth about $23,746,000. 81.09% of the stock is currently owned by institutional investors.
其他一些對衝基金最近也買賣了CCXI的股票。Pictet Asset Management SA在第四季度收購了ChemoCentryx股票的新頭寸,價值約58,453,000美元。千禧管理公司在第四季度將其在ChemoCentryx股票中的頭寸增加了1663.6%。Millennium Management LLC現在擁有這家生物製藥公司1,228,224股股票,價值44,720,000美元,上個季度又購買了1,306,776股。馬歇爾·華斯有限責任公司在第四季度收購了ChemoCentryx股票的新頭寸,價值約30,184,000美元。Sofinnova Investments Inc.在第四季度將其在ChemoCentryx的持倉增加了6,040.6%。Sofinnova Investments Inc.現在持有這家生物製藥公司731,222股股票,價值26,624,000美元,上個季度又購買了719,314股。最後,GW&K Investment Management LLC在第四季度收購了ChemoCentryx的一個新頭寸,價值約23,746,000美元。81.09%的股票目前由機構投資者持有。
Insider Activity
內幕活動
In other news, CEO Thomas J. Schall sold 130,000 shares of the stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $50.24, for a total transaction of $6,531,200.00. Following the sale, the chief executive officer now directly owns 2,393,352 shares of the company's stock, valued at $120,242,004.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Thomas J. Schall sold 130,000 shares of the stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $50.24, for a total transaction of $6,531,200.00. Following the sale, the chief executive officer now directly owns 2,393,352 shares of the company's stock, valued at $120,242,004.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Susan M. Kanaya sold 46,298 shares of the firm's stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $50.17, for a total transaction of $2,322,770.66. Following the completion of the transaction, the chief financial officer now directly owns 91,317 shares in the company, valued at $4,581,373.89. The disclosure for this sale can be found here. Insiders have sold 213,760 shares of company stock valued at $10,749,838 over the last three months. 8.30% of the stock is owned by insiders.
在其他消息方面,首席執行官託馬斯·J·舒爾在8月4日(星期四)的一筆交易中出售了13萬股該公司股票。這些股票以50.24美元的平均價格出售,總成交金額為6,531,200.00美元。出售後,首席執行官現在直接擁有2393,352股公司股票,價值120,242,004.48美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可通過美國證券交易委員會網站獲得。在其他消息方面,首席執行官託馬斯·J·舒爾在8月4日(星期四)的一筆交易中出售了13萬股該公司股票。這些股票以50.24美元的平均價格出售,總成交金額為6,531,200.00美元。出售後,首席執行官現在直接擁有2393,352股公司股票,價值120,242,004.48美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可通過美國證券交易委員會網站獲得。此外,首席財務官Susan M.Kanaya在8月4日(星期四)的一次交易中出售了46,298股該公司的股票。這些股票的平均價格為50.17美元,總成交額為2,322,770.66美元。交易完成後,首席財務官現在直接擁有該公司91,317股,價值4,581,373.89美元。此次拍賣的披露信息可在此處找到。在過去的三個月裏,內部人士已經出售了213,760股公司股票,價值10,749,838美元。8.30%的股份由內部人士持有。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
ChemoCentryx Price Performance
ChemoCentryx性價比
CCXI opened at $51.49 on Monday. ChemoCentryx, Inc. has a one year low of $14.95 and a one year high of $51.78. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.54 and a quick ratio of 4.47. The company's 50 day simple moving average is $38.44 and its 200-day simple moving average is $28.43. The stock has a market capitalization of $3.67 billion, a P/E ratio of -27.24 and a beta of 1.25.
CCXI週一開盤報51.49美元。ChemoCentryx,Inc.的一年低點為14.95美元,一年高位為51.78美元。該公司的債務權益比為0.02,流動比率為4.54,速動比率為4.47。該公司的50日簡單移動均線切入位在38.44美元,200日簡單移動均線切入位在28.43美元。該股市值為36.7億美元,市盈率為-27.24,貝塔係數為1.25。
ChemoCentryx Company Profile
ChemoCentryx公司簡介
(Get Rating)
(獲取評級)
ChemoCentryx, Inc, a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
ChemoCentryx,Inc.是一家生物製藥公司,專注於在美國開發和商業化治療炎症性疾病、自身免疫性疾病和癌症的新藥。它提供TAVNEOS(Avacopan),一種口服的選擇性C5aR抑制劑,用於治療嚴重的抗中性粒細胞胞漿抗體相關小血管炎的成人患者。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on ChemoCentryx (CCXI)
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
- Here's Why the CPI Report will Dictate the Market Bottom
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- 免費獲取StockNews.com關於ChemoCentryx(CCXI)的研究報告
- 電子藝界能扭轉電子遊戲市場的低迷嗎?
- 美元將軍是美國小池塘裏的大魚。
- 以下是CPI報告將決定市場底部的原因
- MarketBeat:回顧一週9/5-9/9
- 為網絡安全股創紀錄的季度做準備
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.
接受ChemoCentryx日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對ChemoCentryx和相關公司的最新新聞和分析師評級的每日簡要摘要。